Karyopharm and Ono collaboration could be worth $200 million plus

Nasdaq-listed Karyopharm Therapeutics and Japan’s Ono Pharmaceutical have agreed a co-development deal for oncology candidates selinexor and KPT-8602 in Asia.

Karyopharm will receive a one-time upfront payment of $22.3 million from Ono and retains all rights to selinexor and KPT-8602 outside the agreed territory.

Up to $170 million is also payable if certain development and commercial milestones are reached, as well as low double-digit royalties based on future net sales.

Ono will receive exclusive rights to develop and commercialize both compounds in the agreed countries, and will be able to participate in any global clinical study of selinexor and KPT-8602.